Health Studies Updates
1.1K views | +0 today
Follow
Health Studies Updates
Ideas, news and information for any health professional. Check my social networks at: http://xeeme.com/Natalie_Stewart
Your new post is loading...
Your new post is loading...
Scooped by Natalie Stewart
Scoop.it!

New rule on vaccine to help fight meningitis in remotest Africa

New rule on vaccine to help fight meningitis in remotest Africa | Health Studies Updates | Scoop.it
A cheap meningitis vaccine designed to treat a type of the disease common in Africa was ruled safe to use after several days without refrigeration on Wednesday, allowing health workers to get it to people in more remote parts.

Epidemics of meningitis A occur every seven to 14 years in Africa's "meningitis belt", a band of 26 countries stretching from Senegal to Ethiopia, and are particularly devastating to children and young adults.

The World Health Organisation (WHO) ruling, that vaccine MenAfriVac is safe to use for up to four days at up to 40 degrees Celsius, will save money spent on expensive "cold chain" systems in the final miles of delivery, said Orin Levine, director of vaccine delivery at the Bill & Melinda Gates Foundation, which helped fund the vaccine's development.

more...
No comment yet.
Scooped by Natalie Stewart
Scoop.it!

Second Illness Infects Meningitis Sufferers

Second Illness Infects Meningitis Sufferers | Health Studies Updates | Scoop.it

People recovering from meningitis in a national outbreak are now being diagnosed with epidural abscesses.

An epidural abscess is an infection near the spine at the site where the drug — contaminated by a fungus — was injected to treat back or neck pain. The abscesses are a localized infection, different from meningitis, which affects the membranes covering the brain and spinal cord. But in some cases, an untreated abscess can cause meningitis. The abscesses have formed even while patients were taking powerful antifungal medicines, putting them back in the hospital for more treatment, often with surgery.

more...
No comment yet.